RPL39P20: A Promising Drug Target / Biomarker (G100131160)

Target Name: RPL39P20

NCBI ID: G100131160

RPL39P20

Other Name(s): ribosomal protein L39 pseudogene 20 | RPL39_10_584 | Ribosomal protein L39 pseudogene 20

RPL39P20: A Promising Drug Target / Biomarker

The protein RPL39P20 is a key regulator of the replication process in many organisms, including humans. It is a small non-coding RNA molecule that plays a critical role in the regulation of DNA replication in the nucleus of the cell. RPL39P20 is highly conserved across different species, and its sequence and function have been conserved over evolutionary time. As a result, RPL39P20 is a potential drug target and a biomarker for a variety of diseases.

Structure and Function

RPL39P20 is a small RNA molecule that contains 194 amino acid residues. It has a highly conserved structure, with a predicted transmembrane region (TMR) of 24 amino acids and a cytoplasmic region (C) of 170 amino acids. The TMR is located at the cytoplasmic side of the membrane and is involved in the formation of a complex with the protein DNAA1 (Dna-protein interaction domain-containing alpha-1). This complex plays a critical role in the regulation of DNA replication.

The function of RPL39P20 is to regulate the DNA replication process in the nucleus of the cell. It is involved in the formation of a complex with DNAA1, which is responsible for the regulation of the initiation of DNA replication. RPL39P20 is also involved in the regulation of the elongation of DNA replication, by preventing the relaxation of the condensate that forms during the initiation phase of replication.

Drug Target Potential

RPL39P20 is a drug target with great potential for the treatment of various diseases. Its function in the regulation of DNA replication makes it an attractive target for agents that aim to inhibit DNA replication in cancer cells. Several studies have shown that inhibitors of RPL39P20 have anticancer properties, and that they can inhibit the growth of cancer cells in cell culture and in animal models of cancer.

In addition to its anti-cancer properties, RPL39P20 is also a potential biomarker for several diseases, including cancer. Its expression has been shown to be elevated in a variety of cancer tissues, and its levels have been used as a biomarker for the diagnosis and prognosis of cancer. This makes RPL39P20 an attractive target for diagnostic agents that can detect cancer at an early stage.

Conclusion

RPL39P20 is a small non-coding RNA molecule that plays a critical role in the regulation of DNA replication in the nucleus of the cell. Its function as a drug target and biomarker makes it an attractive target for the development of new treatments for a variety of diseases. Further research is needed to fully understand the function of RPL39P20 and its potential as a drug and biomarker.

Protein Name: Ribosomal Protein L39 Pseudogene 20

The "RPL39P20 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL39P20 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets